Breast Cancer Survivors Have Increased Risk of Implant-Associated ALCL
Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
AEs Related to Antibody-Drug Conjugates Most Common in Breast Cancer
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
FDA Approves Additional Dosing Schedule for Rylaze
The new dosing option was approved based on data from a phase 2/3 trial.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Adcetris Approved for Pediatric Patients With High-Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Proteinuria, AKI With New Tyrosine Kinase Inhibitors Characterized
Proteinuria was more frequent with regorafenib than with axitinib.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Substituting Brentuximab Vedotin for Bleomycin Improves EFS in Pediatric Hodgkin Lymphoma
Brentuximab vedotin improved event-free survival but not overall survival.
Breast Implant-Associated Cancers: What Providers and Patients Need to Know
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
Tucidinostat Deemed Promising in Relapsed/Refractory Peripheral T-Cell Lymphoma
Tucidinostat appears safe and effective in patients with relapsed/refractory peripheral T-cell lymphoma.
Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Risk of VTE 6-Fold Higher in CLL/MBL Than in General Population
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
COVID-19 Vaccination Should Not Interrupt ICI Therapy, Researchers Say
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Exercise Intervention During Chemotherapy Beneficial
Exercise during chemotherapy may preserve cardiorespiratory fitness, a study suggests.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...